Search International and National Patent Collections

1. (WO2018163066) NOVEL IMIDAZO[4,5-C]QUINOLINE DERIVATIVES AS LRRK2 INHIBITORS

Pub. No.:    WO/2018/163066    International Application No.:    PCT/IB2018/051439
Publication Date: Fri Sep 14 01:59:59 CEST 2018 International Filing Date: Wed Mar 07 00:59:59 CET 2018
IPC: C07D 471/04
C07D 519/00
A61K 31/437
A61P 25/16
A61P 25/28
A61P 25/18
Applicants: PFIZER INC.
Inventors: BRODNEY, Michael Aaron
CHAPPIE, Thomas Allen
CHEN, Jinshan Michael
COE, Jotham Wadsworth
COFFMAN, Karen Jean
GALATSIS, Paul
GARNSEY, Michelle Renee
HELAL, Christopher John
HENDERSON, Jaclyn Louise
KORMOS, Bethany Lyn
KURUMBAIL, Ravi G.
MARTINEZ-ALSINA, Luis Angel
PETTERSSON, Martin Youngjin
REESE, Matthew Richard
ROSE, Colin Richard
STEPAN, Antonia Friederike
VERHOEST, Patrick Robert
WAGER, Travis T.
WARMUS, Joseph Scott
ZHANG, Yuan
Title: NOVEL IMIDAZO[4,5-C]QUINOLINE DERIVATIVES AS LRRK2 INHIBITORS
Abstract:
The present invention provides novel imidazo[4,5-c]quinoline derivatives of Formula (I), and the pharmaceutically acceptable salts thereof I wherein R1, R2 and R3 are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of Formula I and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.